![]() |
Dedicated to NPs, PAs and rheumatologists who diagnose and treat arthritis and other musculoskeletal conditions.
|
|
key topics
navigation |
Biologics And Rheumatoid ArthritisPoint/Counterpoint: Should You Prescribe Steroids For Rheumatoid Arthritis? Yes, Dr. Deane says many studies have pointed to the positive results of treating rheumatoid arthritis (RA) with glucocorticoids. No, Dr. Goldman says corticosteroids have a significantly reduced role in the treatment of RA. Emerging Agents For RA: Can They Have An Impact? Given the recent advances in the understanding of rheumatoid arthritis, these authors offer a closer look at the pathogenesis of the disease and the potential impact of biologic therapies. Biologics For Psoriatic Arthritis: Can They Have An Impact? Reviewing the challenges of detecting and managing psoriatic arthritis, this author offers key insights on the differential diagnosis of the disease. Drawing upon his clinical experience and a couple of case studies, he also discusses the role of biologic response modifiers within the treatment armamentarium for this condition. Biologic Therapy For RA: What You Should Know In this month?s Q&A, the panelists explore biologic therapy in the treatment of rheumatoid arthritis (RA). Sharing their clinical experiences, they discuss key considerations for the use of these agents, the potential for patient resistance, how to gauge efficacy and monitor for potential side effects. A Closer Look At Combination Therapy For RA Given the debilitating effects of rheumatoid arthritis and recent changes in the evolution of RA treatment, these authors review the literature and discuss the potential impact of combination therapy for this disease. Current Concepts In Detecting And Treating RA In the debut of our ?Rheumatoid Arthritis? Q&A column, the expert panelists take a closer look at whether the blood test for rheumatoid factor (RF) can be beneficial in diagnosing rheumatoid arthritis (RA). They also discuss the evolution of methotrexate as a first-line treatment therapy. Without further delay, here is what the panelists had to say. Pregabalin Gains FDA Approval For Fibromyalgia The 100-patient study, which was recently published in the Journal of Rheumatology, found that 39 percent of patients studied achieved an ACR 20 response at 12 weeks after having subcutaneous injections of adalimumab 40 mg every other week. Revealing RA’s Impact On Sleep: What One Study ShowsBy Aaron Becker, Associate Editor A recent study published in Musculoskeletal Care determined that 35 percent of the rheumatoid arthritis (RA) patients enrolled experienced sleep disruption that ... Secrets To Coding For RA And Osteoporosis Drugs Secrets To Coding For RA And Osteoporosis Drugs Coding Corner: Secrets To Coding For RA And Osteoporosis Drugs - By Antanya A. Chung, CPC and Melesia R. Collins, CPC Rheumatoid arthritis (RA) usually requires a lifelong treatment regimen that may include medications, physical therapy, exercise, education and possibly surgery. Clinicians may prescribe disease-modifying antirheumatic drugs (DMARDs) after less potent drugs prove to be ineffective for a patient. Other DMARDs Clinicians May ... RA Study: Etanercept Shows Sustained Efficacy For Up To Nine Years In assessing 77 patients with early RA and 280 patients with longstanding RA who completed eight years of treatment with etanercept, researchers found that 75 percent of patients with early RA and 76 percent of those with longstanding RA achieved an ACR 20 score. A.L. Study Says: Abatacept Offers Sustained Benefits In RA Patients After two years of receiving treatment with abatacept, patients with RA maintained significant improvements, according to study findings that were presented ... Assessing Older DMARDs And The Roles Of Diet In Treating RA In this column, our panelists discuss the possible use of older disease-modifying antirheumatic drugs (DMARDs) in managing rheumatoid arthritis (RA), whether nutrition can have an impact in these patients, and the role of magnetic resonance imaging (MRI) in diagnosing RA and monitoring patient progress. Without further delay, here is what our panelists had to say.
|
July 19, 2008
A complimentary CME Webcast Event |